# US 5,702,906 A · Antibodies to neurotrophic factor-4 (NT-4)

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 5,702,906 A
- Document ID: US5702906A
- Status: Granted
- Kind: A
- Application number: 08/451,947
- Filed: 1995-05-26
- Granted: 1997-12-30
- Earliest claimed: 1990-09-25
- Assignees: Genentech, Inc.
- Inventors: Arnon Rosenthal
- Web page: https://patentgrep.com/patent/US5702906A

## CPC

- C07K 14/475: Growth factors; Growth regulators
- C07K 16/22: against growth factors {; against growth regulators}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

A novel polypeptide, designated neurotrophic factor-4 (NT-4), has been identified by PCR amplification of human genomic DNA. Provided herein is nucleic acid encoding NT-4 useful in diagnostics and in the recombinant preparation of NT-4. Also provided herein are nucleic acids encoding naturally occurring amino acid sequence variants of NT-4, designated NT-4.beta., NT-4.gamma., and NT-4.DELTA.. The neurotrophic factors of the invention are useful in the treatment of nerve cells and in diagnostic assays.

## Claims

### Claim 1

An antibody that binds neurotrophic factor-4 (NT-4) but that does mot bind NGF, BDNF, or NT-3.

### Claim 2

A monoclonal antibody that binds NT-4, but that does not bind NGF, BDNF, or NT-3.

### Claim 3 (depends on 1)

A method for detecting NT-4 in vitro or in vivo comprising contacting the antibody of claim 1 with a test sample, detecting binding of antibody to NT-4 in the test sample, and correlating the binding to the presence of NT-4.

### Claim 4 (depends on 1)

A method for purifying NT-4 comprising passing a mixture of NT-4 over a column to which is bound an antibody of claim 1 and recovering the purified NT-4.

### Claim 5 (depends on 1)

A composition comprising the antibody of claim 1 and a physiologically acceptable carrier.

### Claim 6 (depends on 1)

The antibody of claim 1 that is labelled.

### Claim 7 (depends on 6)

The antibody of claim 6 that is a monoclonal antibody.

### Claim 8 (depends on 7)

A hybridoma cell line that produces the antibody of claim 7.

### Claim 9 (depends on 3)

The method of claim 3 where the use is in vitro.

### Claim 10 (depends on 9)

The method of claim 9, wherein the antibody is labelled.